Homozygous missense WIPI2 variants cause a congenital disorder of autophagy with neurodevelopmental impairments of variable clinical severity and disease course

Reza Maroofian,1,* Andrea Gubas,2,* Rauan Kaiyrzhanov,1,* Marcello Scala,1,3,4,* Khalid Hundallah,5 Mariasavina Severino,6 Mohamed S. Abdel-Hamid,7 Jill A. Rosenfeld,8,9 Darius Ebrahimi-Fakhari,10 Zahir Ali,11 Fazal Rahim,12 Henry Houlden,1 Sharon A. Tooze,13 Norah S. Alsaleh14 and Maha S. Zaki15

* These authors equally contributed to the work.

WIPI2 is a member of the human WIPI protein family (seven-bladed b-propeller proteins binding phosphatidylinositols, PROPPINs), which play a pivotal role in autophagy and have been implicated in the pathogenesis of several neurological conditions. The homozygous WIPI2 variant c.745G>A; p.(Val249Met) (NM_015610.4) has recently been associated with a neurodevelopmental disorder in a single family. Using exome sequencing and Sanger segregation analysis, here, two novel homozygous WIPI2 variants [c.551T>G; p.(Val184Gly) and c.724C>T; p.(Arg242Trp) (NM_015610.4)] were identified in four individuals of two consanguineous families. Additionally, follow-up clinical data were sought from the previously reported family. Three non-ambulant affected siblings of the first family harbouring the p.(Val184Gly) missense variant presented with microcephaly, profound global developmental delay/intellectual disability, refractory infantile/childhood-onset epilepsy, progressive tetraplegia with joint contractures and dyskinesia. In contrast, the proband of the second family carrying the p.(Arg242Trp) missense variant, similar to the initially reported WIPI2 cases, presented with a milder phenotype, encompassing moderate intellectual disability, speech and visual impairment, autistic features, and an ataxic gait. Brain MR imaging in five patients showed prominent white matter involvement with a global reduction in volume, posterior corpus callosum hypoplasia, abnormal dentate nuclei and hypoplasia of the inferior cerebellar vermis. To investigate the functional impact of these novel WIPI2 variants, we overexpressed both in WIPI2-knockout HEK293A cells. In comparison to wildtype, expression of the Val166Gly WIPI2b mutant resulted in a deficient rescue of LC3 lipidation whereas Arg224Trp mutant increased LC3 lipidation, in line with the previously reported Val231Met variant. These findings support a dysregulation of the early steps of the autophagy pathway. Collectively, our findings provide evidence that biallelic WIPI2 variants cause a neurodevelopmental disorder of variable severity and disease course. Our report expands the clinical spectrum and establishes WIPI2-related disorder as a congenital disorder of autophagy.

1 Department of Neuromuscular Diseases, University College London, Queen Square, Institute of Neurology, London, UK
2 Goethe University Medical School, University Hospital, 60590 Frankfurt am Main, Germany
3 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy
4 Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini, Genoa, Italy
5 Division of Neurology, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
6 Neuroradiology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy

Received March 17, 2021. Revised June 22, 2021. Accepted June 30, 2021
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: WIPI2; WIPI2b; autophagy; neurodevelopmental disorder; congenital disorders of autophagy

Abbreviations: ATG12 = autophagy-related 12; ATG16L1 = autophagy 16-like 1; ATG5 = autophagy-related 5; BPAN = beta-propeller protein-associated neurodegeneration; CADD = combined annotation-dependent depletion; CRISPR = Clustered Regularly Interspaced Short Palindromic Repeats; EBSS = Earle’s Balanced Salt Solution; EDTA = ethylenediamine tetraacetic acid; ESP = Exome Sequencing Project; FRRG = Phenylalanine-Arginine-Arginine-Glycine; GERP = Genomic Evolutionary Rate Profiling; HEK293A = human embryonic kidney 293 A; IDDSSA = Intellectual Developmental Disorder with Short stature and variable Skeletal Anomalies; KO = knock-out; LC3 = Microtubule-associated protein 1A/1B-light chain 3; LC3B = microtubule-associated protein 1A/1B-light chain 3 B; MR = magnetic resonance; NEDSBAS = Neurodevelopmental disorder with spastic quadriplegia and brain abnormalities with or without seizures; NHLBI = National Heart, Lung and Blood Institute; OMIM = Online Mendelian Inheritance in Man; PhosSTOP = phosphatase inhibitors; PI(3)P = phosphatidylinositol 3-phosphate; PI(3,5)P2 = phosphatidylinositol 3,5-bisphosphate; pLOF = Predicted loss-of-function; PVDF = polyvinylidene difluoride; SDS = sodium dodecyl sulfate; SUMF1 = Sulfatase Modifying Factor 1; WDR45 = WD repeat-containing protein 45; WDR45B = WD repeat-containing protein 45 B; WIPI = WD40 repeat protein interacting with phosphoinositides; WT = wild type

Graphical Abstract

Homozygous nonsense WIPI2 variants cause a congenital disorder of autophagy with neurodevelopmental impairments of variable clinical severity and disease course

[Diagram showing genetic variant effects on autophagic flux and its impact on clinical outcomes]
### Introduction

The human WIPI family encompasses 4 members (WIPI1-4) known as seven-bladed β-propeller proteins that bind phosphatidylinositol-3-phosphate (PI(3)P) and phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2) and are involved in autophagy.\(^1\)-\(^3\) Pathogenic variants in the WIPI genes are associated with several neurological conditions (Supplementary Table 1). **De novo** variants in WIPI4 (WDR45, OMIM #300526) cause an X-linked neurodegenerative condition known as beta-propeller protein-associated neurodegeneration (BPAN, OMIM #300894).\(^4\),\(^5\) Biallelic variants in WIPI3 (WDR45B, OMIM #609226) cause a syndrome known as a neurodevelopmental disorder with spastic quadriplegia and brain abnormalities with or without seizures (NEDSBA, OMIM #617977), characterized by progressive neurodevelopmental deterioration with pyramidal and extrapyramidal features as well as musculoskeletal abnormalities.\(^6\) Additionally, **de novo** loss-of-function missense variants in WIPI1 (OMIM #609224) have recently been detected in a large cohort of anencephalic cases, suggesting a possible role in embryonic brain development and neural tube formation.\(^7\) Very recently, both monoallelic and biallelic variants in WIPI2 (OMIM #609225) have been reported to be associated with neurological conditions.\(^8\),\(^9\)

WIPI2 (mainly the WIPI2b isoform) plays a crucial role in the formation of the phagophore, the initial step of the highly-conserved, self-degradative, and dynamic recycling process, known as autophagy.\(^10\),\(^11\) WIPI2b isoform is 18 amino acids shorter than the main, full-length isoform, WIPI2a, where Val184Gly and Arg242Trp mutations correspond to Val166Gly and Arg224Trp, respectively. According to studies on the yeast orthologue HSV2, WIPI2 exhibits a PI(3)P- and (PI(3,5)P2)-binding activity within the FRRG motif, at 2 sites, (site 1 and site 2), localized on blades 5 and 6.\(^9\),\(^12\),\(^13\) After the PI(3)P-rich omegasome is generated from the endoplasmic reticulum, WIPI2 (WIPI2b and WIPI2d isoforms) recruits the ATG12–ATG5–ATG16L1 complex to the phagophore, enabling LC3 lipidation and fostering autophagosome formation.\(^1\),\(^14\) Proper functioning of the autophagic molecular machinery is essential for neuronal homeostasis and survival.\(^11\) Abnormal autophagy is involved in the pathogenesis of several neurodegenerative disorders and single-gene defects in key autophagy proteins lead to childhood-onset neurological disorders.\(^15\)-\(^17\)

The **de novo** missense variant c.914A>G; p.(Tyr305Cys) (NM_015610.4) in WIPI2 was first reported as a candidate for cerebral palsy after its identification in a female with hemiplegia, hydrocephalus and periventricular leukomalacia.\(^8\) Subsequently, the homozygous missense variant c.745G>A; p.(Val249Met) (NM_015610.4) was identified as the cause of a new neurodevelopmental disorder in four individuals from a large consanguineous family living in a remote area of Northern Pakistan.\(^9\) Clinical data in this family were scarce and limited to only two affected individuals (Table 1). The disorder is currently known as Intellectual Developmental Disorder with Short stature and variable Skeletal Anomalies (IDDSSA, OMIM #618453), characterized by impaired intellectual development, behavioural abnormalities, ventriculomegaly, dysmorphic features, mild skeletal abnormalities.\(^9\)

Here, we report four individuals from two consanguineous families harbouring two ultra-rare homozygous WIPI2 missense variants and presenting with a neurodevelopmental disorder. In addition, we re-evaluate data from previously reported cases with a homozygous WIPI2 variant including additional clinical details and brain MRI findings. Using functional assays in cultured cells, we demonstrated that disease-associated WIPI2 variants cause dysregulation of autophagy. Collectively, these findings confirm the causality of biallelic missense variants in WIPI2 and expand the molecular and phenotypic spectrum of this emerging congenital disorder of autophagy.

### Materials and methods

#### Clinical and genetic studies

In this study, we evaluated two independent consanguineous families of Egyptian and Saudi origin (Fig. 1A). We also collected follow-up data from two previously reported cases from a Pakistani family.\(^9\) The study was approved by the institutional ethics committees of the participating centres and written informed consent was obtained from the families, in accordance with the Declaration of Helsinki. Detailed clinical features as well as family history were obtained from all affected individuals and reviewed carefully by a group of clinical geneticists (M.Z. and N.A.) and pediatric neurologists (M.S., R.K., H.H. and D.F.E.). Brain MRIs were reviewed by an experienced neuroradiologist (M.S.). Clinical exome sequencing and Sanger segregation analysis were performed independently at two different accredited diagnostic laboratories, Centogene and Baylor Genetics.

#### Cell culture and plasmids

HEK293A wildtype and WIPI2 CRISPR KO cells (Gubas et al., unpublished data) were maintained in Dulbecco’s Modified Eagle’s Medium, supplemented with 10% Fetal Bovine Serum and 1% Penicillin and Streptomycin. The cells were transiently transfected for 24 h using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. To induce amino acid starvation, Earle’s Balanced Salt Solution (EBSS) was used for two hours in the presence or absence of 100 nM Bafilomycin A1 (Calbiochem). pcDNA3.1 was used as an empty vector control. WIPI2b-HA WT plasmid was a kind gift from previously reported cases with a homozygous WIPI2 variant including additional clinical details and brain MRI findings.
| Families (Ancestry) | Family I (Egypt) | Family II (Saudi Arabia) | Jelani et al.9; 1 Family (Pakistan) |
|--------------------|-----------------|--------------------------|-----------------------------------|
| **Individuals**    | **F1-IV-1**     | **F1-IV-3**              | **F1-IV-4**                       | **NA (IV-4)** | **AA (V-3)** |
| Age, sex           | 13 years, F (deceased at 14 y) | 11.4 years, M | 7.5 years, F | 5 years, F | NA (V-4) | 50 years, M | 47 years, M |
| Consanguinity      | +               | +                        | +                                 | +              | +            | +              | +            |
| WIP12 variant      | c.551T>G;       | c.551T>G;                | c.724C>T;                         | c.745G>A;      | c.745G>A;      |
| (NM_015610.4)      | p.(Val184Gly)   | p.(Val184Gly)            | p.(Arg242Tyr)                     | p.(Val249Met)  | p.(Val249Met)  |
| Status             | Hom             | Hom                      | Hom                               | Hom            | Hom          | Hom            | Hom          |
| Pregnancy          | Unevento         | Unevento                 | Unevento                          | Preterm birth  (30 weeks) | Unevento | Unevento | Unevento |
| Growth parameters at birth | Normal | Normal | Normal | Normal weight reported | Normal weight reported | Normal weight reported |
| Growth parameters at last evaluation | W 12.5 kg (−3.5 SDs) | W 11 kg (−3.1 SDs) | W 11 kg (−3.3 SDs) | W 16.8 kg (−0.17 SDs) | N/A | N/A | N/A |
| | H 110 cm (−7 SDs) | H 106 cm (−5.8 SDs) | H 101 cm (−4 SDs) | H 101.5 cm (−0.84 SDs) | N/A | N/A | N/A |
| OFC 47 cm (−4.9 SDs) | OFC 46.5 cm (−4.9 SDs) | OFC 47.5 cm (−3.1 SDs) | OFC 48.5 cm (−0.71 SDs) | OFC 48.5 cm (−0.71 SDs) | N/A | N/A | N/A |
| Congenital MC      | −               | −                        | −                                 | −              | −            | −              | −            |
| Acquired MC        | +               | +                        | +                                 | −              | −            | −              | −            |
| Feeding difficulties| +               | +                        | +                                 | −              | −            | −              | −            |
| Development        | Motor            | Severely delayed         | Severely delayed                  | Severely delayed | Moderately delayed | Delayed        |
|                   | Speech           | Severely delayed         | Severely delayed                  | Severely delayed | Severely delayed | Delayed        |
|                   | Social           | Severely delayed         | Severely delayed                  | Severely delayed | Severely delayed | Delayed        |
|                   | Regression       | +, profound              | +, profound                       | +, profound    | +, severe      | +, moderate    |
|                   | ID               | + (at 1.5 y)             | +, profound                       | +, profound    | +, severe      | +, moderate    |
|                   | Behavioural      | Excessive crying, irritability, poor sleep | Excessive crying, irritability, poor sleep | Irritability | Stereotyped behaviour, irritability, excessive crying, self-injurious behaviour | Enuresis, nocturia, abnormal rational thinking, ISB |
| disturbances      | Seizures         | −                         | −                                 | −              | −            | −              | −            |
|                   | Onset            | 2 years                  | 3 years                           | Infancy        | −            | −              | −            |
|                   | Type             | GMS, TS                  | GMS, TS                           | MS             | −            | −              | −            |
|                   | Frequency        | Weekly                   | Weekly                            | Occasional     | −            | −              | −            |
|                   | Refractory       | +                        | +                                 | N/A            | −            | −              | −            |
|                   | Abnormal EEG     | +                        | +                                 | +              | −            | −              | −            |
|                   | Hypotonia        | −                        | −                                 | −              | −            | −              | −            |
|                   | Sphincter tetraplegia | +                        | +                                 | +              | −            | −              | −            |
|                   | Hyperreflexia    | +                        | +                                 | +              | −            | −              | −            |
|                   | Movement disorders | Dyskinesia               | Dyskinesia                        | Dyskinesia     | Dysarthria and mild gait ataxia | Dysarthria and mild gait ataxia |
|                   | Other neurological problems | Rigidity, drooling | Rigidity, drooling | Rigidity | Impaired memory | Impaired memory |
|                   | Facial dysmorphia | +                        | +                                 | +              | −            | +              |
|                   | Short stature    | +                        | +                                 | +              | Mild         | −              |
|                   | Musculoskeletal abnormalities | +                        | +                                 | +              | Mild         | Mild           |
|                   | (continued)      |                          |                                   |                |              |                |              |
### Table 1 Continued

| Muscle wasting | Nystagmus | Nystagmus | Nystagmus | Nystagmus, suspected CRD | Nystagmus, cataracts, age-related macular degeneration |
|---------------|-----------|-----------|-----------|--------------------------|-----------------------------------------------------|
| Ocular features | +         | +         | +         | -                        | +                                                   |
| Abnormal ECG | +         | +         | +         | N/A                      | N/A                                                 |
| Endocrinological features | -         | -         | -         | +                        | +                                                   |
| Other clinical features | Hemolytic anaemia, dysphagia and feeding difficulties | Joint contractures, dysphagia and feeding difficulties | Joint contractures, dysphagia and feeding difficulties | Constipation | Mild digit abnormalities, Variable subclinical cardiac arrhythmias |
| Neuroimaging | WM volume loss | +         | +         | +                        | +                                                   |
|               | Enlarged ventricles | +         | +         | +                        | +                                                   |
|               | CCH         | +         | +         | +                        | N/A                                                 |
|               | WM signal alterations | +         | +         | +                        | +                                                   |
|               | IVH         | +         | +         | +                        | N/A                                                 |
|               | CDN abnormalities | +         | +         | +                        | +                                                   |
|               | Platypondyly | +         | +         | +                        | N/A                                                 |

CCH, corpus callosum hypoplasia; CDN, cerebellar dentate nuclei; CRD, cone–rod dystrophy; ECG, electrocardiogram; EEG, electroencephalogram; F, female; GMS, generalized myoclonic seizures; H, height; Hom, homozygous; ID, intellectual disability; ISB, inappropriate sexual behaviour; IVH, inferior vermis hypoplasia; M, male; MC, microcephaly; MS, myoclonic seizures; N/A, not available; OFC, occipito-frontal circumference; SDs, standard deviations; TS, tonic seizures; W, weight; WM, white matter.
Figure 1 Molecular, clinical and neuroimaging findings in patients with homozygous variants in WIPI2. (A) Pedigree showing consanguinity within the two families and the genotypes of tested individuals, indicated as + (mutated) and − (wild type). (B) Clinical images of the siblings from Family I, F1-IV:3 (a), and F1-IV:4 (b). Case F1-IV:3 has microcephaly, a severe spastic tetraplegia, contractures of the hands/wrist and ankles, and diffuse muscle wasting. Dysmorphic features include a long face with a prominent chin, thick eyebrows, prominent nose, thick alveolar ridge, dental deformities and large ears. Case F1-IV:4 is microcephalic and presents with severe spastic tetraplegia, distal upper and lower extremity contractures, and muscle atrophy. Her dysmorphic features are milder and mainly consisting of a long face, prominent nose, long philtrum, retrognathia and large ears with prominent antihelix. (C) Brain MRIs of the reported subjects from Family I: F1-IV:1 (a), F1-IV:3
from Prof. Adi Kimchi, Weizmann Institute, Israel, and was previously described. V166G and R224W mutants were generated by site-directed mutagenesis. Primers used—V166G (Forward 5’ gcaccatacgaggggctgacctctgg; Reverse 5’ gccataagctgcccctgcagttc) and R224W (Forward 5’ ccagaaagacaaaaactttttgattgtgagagaatgg; Reverse 5’ cttaacctctctcaaaactcaagttttgtctcttg).

**Western blot**

Whole cell lysates were prepared using TNTE lysis buffer [20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA and 0.3% Triton-X100, supplemented with 1× Complete protease inhibitor cocktail (Roche) and 1× PhosSTOP (Roche)]. Lysates were cleared by centrifugation and 4× SDS-Sample buffer was added to the clear supernatant. Samples were boiled for 5 min at 95°C. Proteins were loaded in equal amounts and resolved on Tris-Glycine 4–12% gels (Bio-Rad), following transfer to a PVDF membrane (Millipore). Following incubations with primary and secondary antibodies, the blots were developed using Luminol reagent (Santa Cruz). Mouse antibodies used in this study: anti-WIPI2 (2A2 clone Abcam, ab105459) and Vinculin (Sigma, V9264). Rabbit antibodies used in this study: anti-p62 (Enzo Life Sciences, PW9860) and anti-LC3B (Abcam, ab48394). Densitometry was performed with ImageJ software.

**Statistical analysis**

Statistics were performed using GraphPad Prism 9 software. Statistical analysis was performed by one-way ANOVA with Tukey’s post-test, from three independent experiments.

**Data availability**

The data that support the findings of this study are available from the corresponding authors upon request.

---

**Results**

**Clinical and neuroimaging findings**

Family 1 consists of three affected siblings (two females and one male) born to consanguineous parents of Egyptian origin (Table 1). Elder affected sibling (F1-IV:1) was a 13-year-old girl who first presented with severe global developmental delay and hypotonia during infancy. Starting at the age of 2 years, she has suffered from recurrent and refractory generalized myoclonic and tonic seizures. She displayed microcephaly, non-specific dysmorphic facial features and mild musculoskeletal abnormalities (kyphoscoliosis, pes planus, overlapping toes and contractures of the wrists and hands) (Supplementary Table 2). Neurological examination revealed nystagmus, drooling, dysphagia, a spastic tetraplegia with hyperreflexia, as well as dyskinesia (Fig. 1B). EEG showed an abnormal background with bilateral temporoparietal epileptiform discharges. At 10 years of age, she developed a refractory and severe haemolytic anaemia of unknown aetiology and succumbed to pneumonia-related respiratory failure 3 years later.

Case F1-IV:3 is an 11.4-year-old male sibling, who presented with mild developmental delay in infancy followed by regression at the age of 1.5 years. Since the age of 3, he has suffered from recurrent weekly myoclonic and tonic seizures despite treatment with multiple anti-epileptic drugs. Similar to his sister, his EEG showed bilateral temporal epileptiform activity. Physical examination revealed microcephaly, non-specific dysmorphic facial features, kyphoscoliosis, long fingers and toes, and distal contractures of the hands and ankles (Fig. 1B). Similar to his sibling, his neurological examination showed a non-verbal patient with a combination of severe spastic tetraplegia and intermittent dyskinesia, with significant muscle atrophy and signs of bulbar dysfunction such as drooling and dysphagia (Video 1).

---

**Figure 1 Continued**

(b), and F1-IV:4 (c); Family 2: F2-IV:3 (d); and AA (V-3) (e) from Jelani et al. In all cases, the sagittal T1- and T2-weighted scans show hypoplasia of the corpus callosum, with predominant involvement of the posterior sections (empty arrows) and small inferior cerebellar vermis. In Case F1-IV:1 (a), axial T2-weighted images show a reduction of the white matter bulk with mild ventriculomegaly, enlargement of the frontotemporal subarachnoid spaces and deep white matter hypointensity (arrows). Similar findings, with less prominent white matter signal alterations, can be observed in the axial T1-weighted images of Cases F1-IV:3 (b), F1-IV:4 (c) and F2-IV:3 (d). Marked swelling with T2-hyperintensity of the cerebellar dentate nuclei is noted in Cases F1-IV:1 (a), F1-IV:3 (b) and F1-IV:4 (c) (arrowheads). In Cases F1-IV:1 (a), F1-IV:3 (b), F1-IV:4 (c) and F2-IV:3 (d), sagittal T1-weighted images reveal platyspondyly of the cervical vertebrae (thick arrows). (D) Schematic drawing of the longest WIPI2 transcript (NM_015610.4) consisting of 4445 nucleotides in 13 exons. WIPI2 variants are shown in black (previously reported patients) or in red (this study). (E) The WIPI2 protein (NP_056425.1, isoform a, WIPI2a) consists of 454 amino acids encompassing seven WD repeat domain (seven-bladed b-propeller protein). The conserved arginine residues of the FRRG sequence in the blades 5 and 6 bind two head groups on the PI(3)P participating in the two distinct pockets on the blade 5 (site 1) and 6 (site 2), which play a pivotal role in the binding of phosphatidylinositolos. Amino acid changes are indicated in black (previous cases) and red (this study). (F) Conservation of the affected amino acid residues among different species according to Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/). Gene transcript and protein details are available at https://www.ensembl.org (WIPI2-201, transcript ID ENST00000288828.9), https://www.nextprot.org (NX_Q9Y4P8), https://www.uniprot.org (Q9Y4P8), https://www.proteomicsdb.org (Q9Y4P8).
The youngest sibling (F1-IV:4) is a 7.5-year-old girl with profound intellectual disability. She had myoclonic seizures since early infancy with temporoparietal epileptiform discharges and abnormal slowing background on EEG. Neurological findings were similar to her siblings (Fig. 1B and Video 2).

Family II consists of a 5-year-old female index case (F2-IV:3) born to consanguineous parents of Saudi origin (Table 1). At 11 months, she was diagnosed with global developmental delay and nystagmus. Electroretinography and visual evoked potentials showed bilateral visual pathway involvement suggestive of cone-rod dystrophy. At 5 years of age, she was able to walk with support with a broad-based ataxic gait. The speech was limited to about 20 words. She displayed stereotyped movements, self-injurious behaviours and autistic features. A formal neuropsychological assessment was not performed but her intelligence quotient was estimated to be around 50.

Two affected brothers, reported previously by Jelani et al., were re-assessed as part of this study. No additional features or regression were noticed since the last examination about 5 years prior. At the ages of 47 and 50 years, both patients present with moderate intellectual disability, behavioural abnormalities, hypomimia, bradykinesia, a mildly ataxic gait, subtle dysmorphic features and short stature along with vision impairment caused by cataracts and age-related macular degeneration (Videos 3 and 4). Their two affected cousins, also homozygous for the p.(Val249Met) variant, passed away of an undetermined cause at the ages of 54 and 38 years.

Brain MRI studies of all 4 cases and of one of the cases reported by Jelani et al. revealed corpus callosum hypoplasia with predominant involvement of the splenium. There was a mild to moderate reduction of the periventricular white matter and enlargement of the lateral ventricles in all cases (Fig. 1C). Hypoplasia of the inferior cerebellar vermis and enlargement of frontotemporal subarachnoid spaces was also noted. Non-specific white matter signal changes were observed in 3/5 patients. Marked swelling and T2 hyperintensity of the cerebellar dentate nuclei were present in affected siblings from Family 1 (3/5 cases). In 4/5 patients, platyspondyly was noticed at the cervical level.
Molecular findings

In Family 1, clinical exome sequencing for the index case was carried out at Centogene as previously described, leading to the identification of a novel homozygous missense variant, c.551T>G; p.(Val184Gly) (NM_015610.4), in WIPI2 (Fig. 1D). Sanger Sequencing confirmed the segregation of this variant with the phenotype within the family. The variant is absent from gnomAD, NHLBI Exome Sequencing Project (ESP), and Centogene and Baylor Genetics databases, as well as in Queen Square Genomics database of 20,000 exomes. The variant involves a highly conserved residue (GERP score 5.78 and CADD score 25.8) (Fig. 1F) and is predicted to be damaging/deleterious by most in-silico tools (Supplementary Table 3). Valine at position 184 localizes to a beta-sheet within blade 4 and its substitution with glycine could impact hydrogen bond formation, leading to abnormal blade folding, membrane association, or likely disruption of protein–protein interactions (Fig. 1E).

In Family 2, clinical exome sequencing for the index case was performed at Baylor Genetics as previously described, leading to the identification of the homozygous missense variant c.724C>T; p.(Arg242Trp) (NM_015610.4) in WIPI2 (Fig. 1D). The variant was validated by Sanger sequencing and segregated with the phenotype in all family members. This variant was absent from gnomAD, ESP, Baylor Genetics database and Queen Square Genomics database of ~20,000 exomes. It is predicted to be damaging/deleterious by most of the employed in-silico tools (Supplementary Table 2). Arginine at position 242 is a highly conserved residue within the FRRG motif (GERP score 5.6 and CADD score 24.8) (Fig. 1F), known to be essential for WIPI2 binding to PIPs (Fig. 1E). The substitution of this residue with threonine has been previously reported to block WIPI2b puncta formation during autophagy, resulting in autophagy inhibition. The introduction of a hydrophobic residue, such as tryptophan, might have the opposite effect of a threonine substitution, and potentially promote PIP or membrane binding at a higher rate than fusion and degradation occur, which could lead to accumulation of cargo and aggregates.

In both families, no additional biallelic variants of likely pathogenic significance were identified.

Functional studies of novel missense variants

To investigate the functional consequences of the identified WIPI2 variants, we overexpressed both mutants in HEK293A cells lacking WIPI2 (WIPI2 KO) and looked at LC3 lipida
tion. The cells lacking WIPI2 show a severe defect in LC3 lipida
tion, which is supported by previous reports. We looked if we can rescue LC3 lipida
tion in these cells by overexpressing WIPI2b WT and the two mutant variants.

Interestingly, when we overexpressed WIPI2b-HA wild type (WT) and WIPI2b V166G (corresponding to V184G in the longest isoform of WIPI2, WIPI2a) we observed that WIPI2b V166G mutant failed to rescue LC3 lipida
tion (Fig. 2A). p62 was used as a marker for autophagic cargo degradation. Expectedly, WIPI2b-HA WT was able to rescue LC3 lipida
tion. Further experiments are required to better define the underlying mechanism of action, and understand if this variant impedes PI(3)P binding or inhibits interaction with ATG16L1 or other binding partners. However, considering that the mutation is located on the blade 4, it is likely that association with another protein is affected.

Overexpression of WIPI2b R224W (corresponding to R242 in WIPI2a) mutant in WIPI2 KO cells induced LC3 lipida
tion, which was even stronger than LC3 lipida
tion caused by WIPI2 WT overexpression (Fig. 2B). We observed differences between conditions [untreated, amino
cid starvation (starved) or starved with Bafilomycin A1, where Bafilomycin A1 is used as an inhibitor of the fu
sion between autophagosomes and lysosomes], suggesting dysregulation of autophagic flux when WIPI2 variants are expressed, but also that some degree of autophagic flux is maintained (Fig. 2B). This is further supported by the strong accumulation of p62 cargo marker upon rescue with R224W mutant.

Video 4 One affected sibling reported in Jelani et al. Video shows the paucity of spontaneous movements, hypomimia and bradykinesia.
Discussion

Congenital disorders of autophagy are known to cause multisystem diseases in children with early and severe involvement of the CNS. Neurological manifestations are typically broad, but preferential degeneration of the cerebellar Purkinje cells and long-projecting cortical neurons is seen. Current knowledge of the clinical phenotypes associated with the defective WIPI proteins mostly comes from WDR45 (WIPI4)-associated BPAN, which was first reported almost a decade ago. For phenotypic comparison associated with defects in WIPI2, WIPI3 and WIPI4 genes refer to Fig. 3 and Supplementary Table 1. Cumulative phenotypic analysis of 64 individuals reported by Stige et al. and 123 individuals reported by Adang et al. (~85% are females) with disease-causing WIP14 (WDR45) variants has suggested a highly variable phenotype ranging from a severe and early disease to asymptomatic carriers, which is typically seen in females, most likely due to skewed X-inactivation. In its classic form, BPAN tends to have a biphasic course including developmental delay and seizures predominating in early childhood, followed by a progressive decline of neurological and cognitive functions frequently associated with dystonia and parkinsonism. Early childhood-onset refractory epilepsy, including myoclonic epilepsy, is relatively common. Variable features include limb spasticity, visual impairment, and rarely dysmorphic features including but not limited to microcephaly, hypertelorism, bilateral low-set ears, kyphosis, tapered fingers with fifth finger clinodactyly. Although the clinical data are currently limited to only 10 reported cases, WIPI3 appears to also manifest as an early infantile-onset progressive disease that can be seen in the progressive microcephaly and quadriplegia associated with a progressive cortical and white matter loss on brain MR imaging. Evidence for WIPI3-related neurodegeneration comes from the wipi3-deficient mice model, which suggested a degree of neuronal loss that is more severe than in wipi4-deficient mice. Additionally, wipi3-deficient mice show prominent

Figure 2 The analysis of autophagic flux upon overexpression of WIPI2b mutants. WIPI2 KO HEK293A cells transiently expressing empty vector, WIPI2b-HA WT or either (A) WIPI2b-HA V166G or (B) WIPI2b-HA R224W, were left untreated or treated with EBSS (amino acid starvation) or EBSS with Bafilomycin A1 for 2 h. The cells were lysed and subjected to SDS-PAGE and Western blot. Antibodies to LC3B, p62, WIPI2 and vinculin were used as indicated. N = 3, representative experiment is shown. Statistical analysis of LC3-II levels for each blot was performed by one-way ANOVA with Tukey's post-test. SEM from n = 3. **P < 0.01. F—fed, untreated; S—EBSS starvation; SB—EBSS starvation + Bafilomycin A1.
cerebellar damage, a phenotype that is yet to be described in cases carrying WIPI3 variants. Thus, both WIPI3 and WIPI4 manifest as a spectrum of early-onset neurodevelopmental disorders and later neurodegeneration.

The phenotypes of the families with WIPI2 variants described in the present report were mainly characterized by the early CNS involvement. Although global developmental delay, intellectual disability, posterior corpus callosum hypoplasia and the inferior cerebellar vermis hypoplasia were uniform features, significant interfamilial variability in the clinical spectrum and severity of the disease is noted. Siblings from Family 1 presented with a phenotype similar to WIPI3 cases from the Suleiman et al. report and the initial phase of the severely affected WIPI4 cases. Apart from an early motor regression in Case F1-IV:3, suggestive of a neurodegenerative course, no significant interfamilial variability was present in Family 1. Contrasting this, affected individuals from Family 2 and report by Jelani et al. presented with a milder non-progressive phenotype including mild-to-moderate gait ataxia and retinal abnormalities as well as moderate developmental delay and intellectual disability. Despite the significant phenotypic variability and a limited number of cases, defective WIPI2, similar to other congenital disorders of autophagy, seems to preferentially impact cortical pyramidal neurons and the corticospinal tracts (Family 1 with severe and progressive spasticity) as well as cerebellar Purkinje cells (nystagmus and the inferior cerebellar vermis hypoplasia in all families, and ataxic gait in Case F2-IV:3 and the affected individuals reported by Jelani et al.).

Neuroimaging findings were consistent with the prominent involvement of the white matter. In particular, we identified a thinning of the corpus callosum with prevalent posterior hypoplasia, variably associated with reduced white matter volume and periventricular signal alterations. Of note, long white matter tracts, including the corpus callosum and corticospinal tracts, are frequently involved in inborn disorders of autophagy. In addition, we noted a striking involvement of the cerebellar dentate nuclei that appeared swollen and hyperintense on T2 weighted images in the most severe cases of Family 1. Cerebellar dentate nuclei abnormalities might thus be an imaging marker of clinical severity in WIPI2 deficiency, that need to be confirmed in larger clinical series. Remarkably, wdr45 and wdr45b KO mice exhibit swollen axons with spheroid accumulation in the deep cerebellar nuclei. However, studies based on animal models are needed to verify if similar histological features are also present in WIPI2 deficiency. Finally, we found platyspondyly of the cervical vertebrae in the majority of our patients, further straightening the phenotypic overlap between autophagy disorders and lysosomal storage diseases. Although the exact mechanisms are still unclear, it has been demonstrated that dysregulation of the autophagic response is involved in the pathogenesis of diseases of bone (Paget disease) and cartilage (osteoarthritis and the mucopolysaccharidoses). In particular, vertebral body abnormalities, including wedge-shaped vertebral

Figure 3 Phenotypic comparison between WIPI2, WIPI3 and WIPI4. (A) Frequency of symptoms. (B) Frequency of neuroradiological findings. (C) Range of phenotype severity. The actual numbers leading to the displayed percentages are provided in Supplementary Table 1.
bodies, anterior beaking with posterior scalloping and platyspondyly, are observed in subjects with multiple sulfatase deficiency, a very severe form of mucopolysaccharidoses due to mutations in the \textit{SUMF1} (sulfatase modifying factor 1) gene.\textsuperscript{28} Multiple measurements of autophagy in the chondrocytes of \textit{sumf1/C0/C0} mice recapitulating the human skeletal anomalies revealed severe lysosomal vacuolization and an increased number of autophagosomes compared with wild-type chondrocytes,\textsuperscript{29,30} providing evidence that abnormal autophagic activity has an impact on the normal growth plate and bone growth.

Taken together, our report expands the phenotypic spectrum of WIPI2-associated disease and highlights severe manifestations shared with other disorders of autophagy, including those caused by \textit{WIPI3} and \textit{WIPI4}.\textsuperscript{5,6} To explore the phenotypic differences among WIPI2 patients (Table 1), we assessed the functional impact of the discovered variants. The p.(Val249Met) variant affects a conserved residue on the surface of the blade 6 adjacent to site 2, leading to abnormal ATG16L1 binding and membrane interaction as a result of impaired PI(3)P and PI(3,5)P2 binding.\textsuperscript{9} The p.(Val184Gly) variant identified in family 1 affects a conserved residue within the blade 4 and the equivalent mutant in WIPI2b is unable to rescue LC3 lipidation fully to the level of WT. Although this domain is not directly implicated in the hitherto identified autophagy-related WIPI2 functions, a loss of function would explain the severe and progressive neurological phenotype as well as the cerebellar dentate nuclei involvement observed in Family 1. The p.(Arg242Trp) variant within the FRRG motif detected in Family 2 might instead lead to dysregulation of early steps of autophagy. Future studies will have to determine the precise molecular impact of this and other missense variants. The functional phenotype of the WIPI2 missense variants reported here is summarized in Fig. 4. Our findings support a loss-of-function mechanism in WIPI2-related disorder, in line with the loss-of-function constraint metrics of WIPI2 (pLOF 0.62) and similarly to other WIPI genes (\textit{WIPI1}, pLOF 0.65; \textit{WIPI3}, pLOF 0.55; \textit{WIPI4}, pLOF 0.21).

WIPI2 phosphorylation is important for neuronal autophagosome biogenesis and is negatively affected by aging.\textsuperscript{31} An age-dependent decline in neuronal autophagy is implicated in several age-dependent neurodegenerative conditions and can be rescued by WIPI2 overexpression.\textsuperscript{31,32} This would suggest that individuals with WIPI2 deficiency might be more prone to early neuronal degeneration, similarly to WIPI3 and WIPI4.\textsuperscript{5,6}

In summary, our study supports that biallelic WIPI2 variants cause a congenital disorder of autophagy, with a wide clinical spectrum and variable disease severity,
possibly explained by the differential impact of different variants on autophagic initiation and flux. Larger, longitudinal studies will be needed to systematically define clinical manifestations of WIPI2-associated disorder. A better understanding of the disease manifestations and the underlying molecular mechanisms will enable the development of targeted therapeutic approaches in the future.

**Web resources**

The following URLs were used for data presented herein:

Centogene; https://www.centogene.com/pharma/mutation-database-centomd.html

ClinVar; https://www.ncbi.nlm.nih.gov/clinvar

Combined Annotation Dependent Depletion (CADD); http://cadd.gs.washington.edu

Ensembl; https://www.ensembl.org/index.html

NHLBI GO Exome Sequencing Project (ESP); https://evs.gs.washington.edu/EVS/

Gene Cards; http://www.genecards.org

Genome Aggregation Database (GnomAD); http://gnomad.broadinstitute.org

Genomic Evolutionary Rate Profiling; http://mendel.stanford.edu/SidowLab/downloads/gerp

Greater Middle East (GME) Variome Project; http://igm.ucsd.edu/gme

Iranome; http://www.iranome.ir

Mutalyzer; https://mutalyzer.nl

Mutation Assessor; http://mutationassessor.org/r3

Mutation Taster; http://www.mutationtaster.org

NeXtProt; https://www.nextprot.org

Online Mendelian Inheritance in Man; http://www.ncbi.nlm.nih.gov/Omim

Polyphen-2; http://genetics.bwh.harvard.edu/pph2

Proteomics DB; https://www.proteomicsdb.org

PubMed; http://www.ncbi.nlm.nih.gov/pubmed

RefSeq; https://www.ncbi.nlm.nih.gov/refseq

SIFT; https://sift.bii.a-star.edu.sg

The 1000 Genomes Browser; http://browser.1000genomes.org/index.html

The Greater Middle East (GME) Variome Project; http://igm.ucsd.edu/gme/index.php

UniProt; https://www.uniprot.org

UCSC Human Genome Database; http://www.genome.ucsc.edu

Varsome; https://varsome.com

**Supplementary material**

Supplementary material is available at *Brain Communications* online.

**Acknowledgements**

The authors would like to thank the patients and their families for their support of this study. This research was conducted as part of the Queen Square Genomics group at University College London, supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

**Funding**

This research was funded in part, by the Wellcome Trust [WT093205MA, WT104033AIA and the Synaptopathies Strategic Award, 165908]. The work at University of Maryland, Baltimore, USA was supported by National Institute of Neurological Disorders and Stroke (NINDS) (R01NS107428) (to S.R.). This study was funded by the Medical Research Council (MR/S01165X/1, MR/S005021/1, G0601943), The National Institute for Health Research University College London Hospitals Biomedical Research Centre, Rosetree Trust, Ataxia UK, Multiple System Atrophy Trust, Brain Research United Kingdom, Sparks Great Ormond Street Hospital Charity, Muscular Dystrophy United Kingdom (MDUK), Muscular Dystrophy Association (MDA USA). S.A.T. was supported by the Francis Crick Institute which receives its core funding from Cancer Research United Kingdom (FC001187), the United Kingdom Medical Research Council (FC001187) and the Wellcome Trust (FC001187). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

**Competing interests**

The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing conducted at Baylor Genetics Laboratories.

**References**

1. Dooley HC, Wilson MJ, Tooose SA. WIPI2B links PtdIns3P to LC3 lipidation through binding ATG16L1. Autophagy. 2015;11(1):190–191.

2. Proikas-Cezanne T, Takacs Z, Donnes P, Kohlbacher O. WIPI proteins: Essential PtdIns3P effectors at the nascent autophagosome. J Cell Sci. 2015;128:207–217.

3. Bakula D, Muller AJ, Zulegar T, et al. WIPI3 and WIPI4 b-propellers are scaffolds for LKB1-AMPK-TSC signalling circuits in the control of autophagy. Nat Commun. 2017;8:15637.

4. Saitsu H, Nishimura T, Muramatsu K, et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet. 2013;45(4):445–449.

5. Seibler P, Burbulla LF, Dulovic M, et al. Iron overload is accompanied by mitochondrial and lysosomal dysfunction in WDR45 mutant cells. Brain. 2018;141(10):3052–3064.

6. Suleiman J, Allingham-Hawkins D, Hashem M, Shamseldin HE, Alkuraya FS, El-Hattab AW. WDR45-related intellectual disability, spastic quadriplegia, epilepsy, and cerebral hypoplasia: A consistent neurodevelopmental syndrome. Clin Genet. 2018;93(2):360–364.

7. Wang L, Ren A, Tian T, et al. Whole-exome sequencing identifies damaging de novo variants in anencephalic cases. Front Neurosci. 2019;13:1285.
8. McMichael G, Bainbridge M, Haan E, et al. Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy. Mol Psychiatry. 2015;20(2):176–182.
9. Jelani M, Dooley HC, Gubas A, et al. A mutation in the major autophagy gene, WIPI2, associated with global developmental abnormalities. Brain. 2019;142(5):1242–1254.
10. Yu L, Chen Y, Tooze SA. Autophagy pathway: Cellular and molecular mechanisms. Autophagy. 2018;14(2):207–215.
11. Doherty J, Baehecreck E. Life, death and autophagy. Nat Cell Biol. 2018;20(10):1110–1117.
12. Baskaran S, Ragu B, Boura E, Hurley C, et al. Structural and functional characterization of the two phosphoinositide binding sites of PROPPINs, a b-propeller protein family. Proc Natl Acad Sci USA. 2012;109(30):E2042–2049.
13. Mizushima N, Komatsu M. Autophagy: Renovation of cells and tissues. Cell. 2011;147(4):728–741.
14. Gilad Y, Shiloh R, Ber Y, Bialik S, Kimchi A. Discovering protein-protein interactions within the programmed cell death network using a protein-fragment complementation screen. Cell Rep. 2014;8(3):909–921.
15. Bauer P, Kandaswamy K, Weiss M, et al. Development of an evidence-based algorithm that optimizes sensitivity and specificity in ES-based diagnostics of a clinically heterogeneous patient population. Genet Med. 2019;21(1):33–41.
16. Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312(18):1870–1879.
17. Watanabe Y, Kobayashi T, Yamamoto H, et al. Structure-based analyses reveal distinct binding sites for Atg2 and phosphoinositides in Atg18. J Biol Chem. 2012;287(38):31681–31690.
18. Haack TB, Hogarth P, Kruer MC, et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet. 2012;91(6):1144–1149.
19. Hayflick S, Krueger M, Gregory A, et al. b-Propeller protein-associated neurodegeneration: A new X-linked dominant disorder with brain iron accumulation. Brain. 2013;136(Pt 6):1708–1717.
20. Ji C, Zhao H, Li D, et al. Role of Wdr45b in maintaining neural autophagy and cognitive function. Autophagy. 2020;16(4):615–625.
21. Settembre C, Spamanato C, et al. Systemic inflammation and neurodegeneration in a mouse model of multiple sulfatase deficiency. Proc Natl Acad Sci. 2007;104(11):4506–4511.
22. Settembre C, Arteaga-Solis E, McKee MD, et al. Proteoglycan desulfation determines the efficiency of chondrocyte autophagy and the extent of FGF signaling during endochondral ossification. Genes Dev. 2008;22(19):2645–2650.
23. Corti O, Blomgren K, Poletti A, Beart PM. Neuronal autophagy declines substantially with age and is rescued by overexpression of WIPI2. Autophagy. 2020;16(2):371–372.